Scientists have engineered swine that pollute less, fend off disease, and produce more meat, but you won’t find them outside experimental farms . . . yet.

Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.

President Trump’s pick, Judge Brett Kavanaugh, has often opposed court involvement in environmental and health regulations.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.

Medical groups have criticized the legislation, which will give terminal patients access to experimental treatments, as dangerous and unnecessary.

Lucemyra is the first non-opioid drug to be approved in the U.S. specifically for this purpose.

Two patients became legally blind after receiving treatments at the facilities.

The Scientist looks at one such Houston-based purveyor that has been treating patients abroad for years with mesenchymal stem cells.